Adaptive trial design is critical in all phases of oncology drug development and helps overcome many hurdles of traditional study design. In a recent webinar, PPD’s Dirk Reitsma, M.D., vice president, global product development, and Niklas Morton, vice president, global biostatistics, programming and medical writing, analyzed the incorporation of adaptive trial design in oncology trials. They were joined by Scott Berry, Ph.D., president and senior statistical scientist with Berry Consultants, to assess the early decision making benefits that are critical to the decreasing drug development time and providing increased benefit to patients.
Will BRIC be the Savior for the Life Sciences and Medical Devices Sector? Discover key lessons from the field and best practices vital to reap rewards from these countries during Frost & Sullivan’s complimentary webinar. The briefing will benefit any senior manager in the corporate strategy or global marketing areas that focuses on emerging markets, as well as any healthcare company looking to explore BRIC countries.
Get your trials up and running faster and your products to market more quickly. Learn how Startup InSite™ technology and the CFS Clinical Contract and Regulatory Services team speeds up the process.
In this webinar, experts will discuss the benefits of using mHealth technology in clinical trials and take a deep dive into the data quality and regulatory considerations that must be evaluated when choosing a medical vs. consumer-grade sensor.
Tufts CSDD presents the findings of a new study assessing practices and inefficiencies associated with site selection, study startup, and site activation in starting clinical trials.
Tufts CSDD presents the findings of a new study assessing practices and inefficiencies associated with site selection, study startup, and site activation in starting clinical trials.
|
|
|
|
|
|
|
|
|